Margaret Folaron1,2, Mukund Seshadri3,4,5. 1. Laboratory for Translational Imaging, Department of Molecular/Cellular Biophysics and Biochemistry, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA. 2. Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA. 3. Laboratory for Translational Imaging, Department of Molecular/Cellular Biophysics and Biochemistry, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA. Mukund.Seshadri@roswellpark.org. 4. Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA. Mukund.Seshadri@roswellpark.org. 5. Department of Head and Neck Surgery, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA. Mukund.Seshadri@roswellpark.org.
Abstract
PURPOSE: The goal of the present study was to examine the safety and efficacy of the vascular disrupting agent (VDA) EPC2407 (Crolibulin™) in experimental glioma models using bioluminescence imaging (BLI) and magnetic resonance imaging (MRI). PROCEDURES: Experimental imaging studies were performed in subcutaneous human U87 glioma xenografts and orthotopic murine gliomas established by intracranial implantation of luciferase-transfected glioma cells (GL261-luc). Correlative histopathology and long-term survival analysis was also performed. RESULTS: Treatment with EPC2407 decreased tumor perfusion and increased necrosis and tumor doubling times in subcutaneous U87 xenografts. Dynamic BLI and T1-weighted contrast-enhanced MRI showed reduction in blood flow of intracranial GL261-luc gliomas within a few hours of VDA treatment. T2-weighted MRI did not show any evidence of hemorrhaging or edema in uninvolved brain tissue of EPC2407-treated animals. A significant increase in median survival (p < 0.05) was observed in the orthotopic GL261-luc model following VDA treatment compared to untreated controls. CONCLUSIONS: We demonstrate, for the first time, the biological activity of EPC2407 in experimental gliomas. Further investigation into the potential of VDAs in combination with chemoradiation therapy against gliomas is warranted.
PURPOSE: The goal of the present study was to examine the safety and efficacy of the vascular disrupting agent (VDA) EPC2407 (Crolibulin™) in experimental glioma models using bioluminescence imaging (BLI) and magnetic resonance imaging (MRI). PROCEDURES: Experimental imaging studies were performed in subcutaneous human U87 glioma xenografts and orthotopic murinegliomas established by intracranial implantation of luciferase-transfected glioma cells (GL261-luc). Correlative histopathology and long-term survival analysis was also performed. RESULTS: Treatment with EPC2407 decreased tumor perfusion and increased necrosis and tumor doubling times in subcutaneous U87 xenografts. Dynamic BLI and T1-weighted contrast-enhanced MRI showed reduction in blood flow of intracranial GL261-luc gliomas within a few hours of VDA treatment. T2-weighted MRI did not show any evidence of hemorrhaging or edema in uninvolved brain tissue of EPC2407-treated animals. A significant increase in median survival (p < 0.05) was observed in the orthotopic GL261-luc model following VDA treatment compared to untreated controls. CONCLUSIONS: We demonstrate, for the first time, the biological activity of EPC2407 in experimental gliomas. Further investigation into the potential of VDAs in combination with chemoradiation therapy against gliomas is warranted.
Authors: E Marleen Kemper; Willem Boogerd; Ingrid Thuis; Jos H Beijnen; Olaf van Tellingen Journal: Cancer Treat Rev Date: 2004-08 Impact factor: 12.111
Authors: Jigisha P Thakkar; Therese A Dolecek; Craig Horbinski; Quinn T Ostrom; Donita D Lightner; Jill S Barnholtz-Sloan; John L Villano Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-22 Impact factor: 4.254
Authors: Casey J Maguire; Zhi Chen; Vani P Mocharla; Madhavi Sriram; Tracy E Strecker; Ernest Hamel; Heling Zhou; Ramona Lopez; Yifan Wang; Ralph P Mason; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney Journal: Medchemcomm Date: 2018-08-24 Impact factor: 3.597
Authors: Haichan Niu; Tracy E Strecker; Jeni L Gerberich; James W Campbell; Debabrata Saha; Deboprosad Mondal; Ernest Hamel; David J Chaplin; Ralph P Mason; Mary Lynn Trawick; Kevin G Pinney Journal: J Med Chem Date: 2019-05-24 Impact factor: 7.446
Authors: Andres M Arias Lorza; Harshan Ravi; Rohit C Philip; Jean-Philippe Galons; Theodore P Trouard; Nestor A Parra; Daniel D Von Hoff; William L Read; Raoul Tibes; Ronald L Korn; Natarajan Raghunand Journal: Sci Rep Date: 2020-09-02 Impact factor: 4.379
Authors: Li Liu; Devin O'Kelly; Regan Schuetze; Graham Carlson; Heling Zhou; Mary Lynn Trawick; Kevin G Pinney; Ralph P Mason Journal: Molecules Date: 2021-04-27 Impact factor: 4.411
Authors: Elizabeth C Randall; Kristina B Emdal; Janice K Laramy; Minjee Kim; Alison Roos; David Calligaris; Michael S Regan; Shiv K Gupta; Ann C Mladek; Brett L Carlson; Aaron J Johnson; Fa-Ke Lu; X Sunney Xie; Brian A Joughin; Raven J Reddy; Sen Peng; Walid M Abdelmoula; Pamela R Jackson; Aarti Kolluri; Katherine A Kellersberger; Jeffrey N Agar; Douglas A Lauffenburger; Kristin R Swanson; Nhan L Tran; William F Elmquist; Forest M White; Jann N Sarkaria; Nathalie Y R Agar Journal: Nat Commun Date: 2018-11-21 Impact factor: 14.919
Authors: Margaret Folaron; Mihai Merzianu; Umamaheswar Duvvuri; Robert L Ferris; Mukund Seshadri Journal: Cancers (Basel) Date: 2019-07-06 Impact factor: 6.639
Authors: Yihang Guo; Honghong Wang; Jeni L Gerberich; Samuel O Odutola; Amanda K Charlton-Sevcik; Maoping Li; Rajendra P Tanpure; Justin K Tidmore; Mary Lynn Trawick; Kevin G Pinney; Ralph P Mason; Li Liu Journal: Cancers (Basel) Date: 2021-09-24 Impact factor: 6.575
Authors: Li Liu; Regan Schuetze; Jeni L Gerberich; Ramona Lopez; Samuel O Odutola; Rajendra P Tanpure; Amanda K Charlton-Sevcik; Justin K Tidmore; Emily A-S Taylor; Payal Kapur; Hans Hammers; Mary Lynn Trawick; Kevin G Pinney; Ralph P Mason Journal: Cancers (Basel) Date: 2022-08-30 Impact factor: 6.575